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Long non-coding RNAs (lncRNAs) form a new class of RNA molecules implicated in various aspects of
protein coding gene expression regulation. To study lncRNAs in cancer, we generated expression proﬁles for
1707 human lncRNAs in the NCI60 cancer cell line panel using a high-throughput nanowell RT-qPCR
platform. We describe how qPCR assays were designed and validated and provide processed and
normalized expression data for further analysis. Data quality is demonstrated by matching the lncRNA
expression proﬁles with phenotypic and genomic characteristics of the cancer cell lines. This data set can be
integrated with publicly available omics and pharmacological data sets to uncover novel associations
between lncRNA expression and mRNA expression, miRNA expression, DNA copy number, protein coding
gene mutation status or drug response
Design Type(s)
disease state design • cell type comparison design • transcription proﬁling by
RT-PCR design
Measurement Type(s) long non-coding RNA expression
Technology Type(s) transcription proﬁling by RT-PCR assay
Factor Type(s) cancer cell line
Sample Characteristic(s)
Homo Sapiens • RCC 786-O cell • A-498 cell • A-549 cell • Colo-205 cell
• DU-145 cell • HOP-62 cell • K-562 cell • MCF-7 cell • MDA-MB-231
cell • MOLT-4 cell • OVCAR-3 cell • OVCA-4 cell • PC-3 cell • SF-268
cell • SF-295 cell • SK-MEL-2 cell • SK-MEL-28 cell • SW-620 cell
• CCRF-CEM cell • HCC-2998 cell • HCT-116 cell • Hs-578T cell
• HOP-92 cell • HT-29 cell • KM-12 cell • LOXIMVI cell • ACHN cell
• BT-549 cell • Caki-1 cell • EKVX cell • HCT-15 cell • HL-60 cell
• IGROV-1 cell • M14 melanoma cell • MALME-3M cell • MDA-MB-435
cell • MDA-MB-468 cell • NCI/ADR-RES cell • NCI-H226 cell • NCI-H23
cell • NCI-H322M cell • NCI-H460 cell • NCI-H522 cell • OVCA-5 cell
• OVCA-8 cell • RPMI-8226 cell • RXF-393 cell • SF-539 cell • SK-MEL-5
cell • SK-OV-3 cell • SN-12C cell • SNB-19 cell • SNB-75 cell • SR cell
• T-47D cell • TK-10 cell • U-251 MG cell • UACC-257 cell • UACC-62
cell • UO-31 cell
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Background & Summary
Genome-wide studies have shown that the human genome is pervasively transcribed, resulting in the
identiﬁcation of tens of thousands of long non-coding RNA (lncRNA) genes. Many lncRNAs are
associated with disease-linked SNPs or show pronounced tissue-speciﬁc expression proﬁles, hinting at a
possible role in human disease and development. The potential importance of lncRNAs (and ncRNAs as
a whole) in development is further supported by the intriguing observation that organismal complexity
(using the number of distinct cell types as a proxy) is strongly correlated to the proportion of the genome
that is non-coding1. During the last few years, a growing number of studies provided evidence that
lncRNA expression is deregulated in cancer and contributes to many of the established cancer hallmarks
(e.g. sustained proliferation, evading apoptosis, invasion and metastasis, angiogenesis, genome instability,
…)2. Notable examples are HOTAIR and MALAT1 that promote metastasis in breast and lung cancer3,4,
PCAT-1 driving proliferation in prostate cancer5, SAMMSON sustaining energy metabolism in
melanoma6 and aHIF regulating angiogenesis in various cancer types7.
To further study the role of lncRNAs in cancer, we measured the expression of 1707 human lncRNAs
in the NCI60 cancer cell line panel using a high-throughput nanowell RT-qPCR platform (SmartChip,
Wafergen) with custom qPCR assays (Fig. 1). These assays were designed using an in-house primer
design pipeline (primerXL), taking into account a series of in silico quality control steps to ensure optimal
assay performance in terms of speciﬁcity and efﬁciency. Upon empirical validation of assay performance,
lncRNA expression was quantiﬁed in all 60 cancer cell lines followed by data processing and
normalization.
The NCI60 cancer cell line panel is one of the best characterized cell line panels for which various
omics data sets (including mRNA and miRNA expression, DNA copy number and cancer gene mutation)
and drug response data are publicly available. Researchers can reuse the lncRNA expression data
described here to study associations with any of the above-described omics data and drug response data
and generate hypotheses on lncRNA functionality in cancer.
Methods
qPCR assay design and validation
Target lncRNA sequences were obtained from ensembl (v61 and v63) and lncRNAdb (v1)
(www.lncRNAdb.org). Whereas lncRNAdb only contains lncRNAs with validated functions, ensembl
is not enriched for functional lncRNAs. LncRNA selections from ensembl were random. For lncRNAs
overlapping (sense or antisense) with protein coding genes, only the non-overlapping lncRNA sequence
was considered for assay design. Detailed annotation of selected lncRNA sequences is available in
Supplementary Table 1.
Assays were designed using the primerXL pipeline (www.primerxl.org), applying stringent design
criteria to ensure optimal assay performance. Primer annealing sites were evaluated for the presence of
SNPs and secondary structures (UNAFold8). Assay speciﬁcity was evaluated using BiSearch9. Assays
devoid of SNPs and secondary structures in primer annealing sites with no predicted ampliﬁcation of
non-target sequences were selected for validation.
All assays were validated by means of a titration-response experiment using the MAQC samples as
reported previously10. In brief, total human reference RNA (MAQC A, Agilent Technologies) and human
brain RNA (MAQC B, Ambion) are combined in a 3:1 or 1:3 ratio to create MAQC C and MAQC D
respectively. Titration response is calculated for each assay in function of the measured expression
difference between MAQC A and MAQC B. In case expression in MAQC A>MAQC B, an assay is
breast (6) cns (6) colon (7)
leukemia (6) melanoma (9) lung (9)
ovarian (7) prostate (2) renal (8)
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Figure 1. Data generation workﬂow. RNA isolated from NCI60 cell lines was reverse transcribed and proﬁled
using 1707 lncRNA assays on a SmartChip system.
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considered ‘titrating’ if MAQC A>MAQC C>MAQC D>MAQC B. In case expression in MAQC
B>MAQC A, an assay is considered ‘titrating’ if MAQC B>MAQC D>MAQC C>MAQC A.
For a subset of 92 (single exonic) assays we determined ampliﬁcation efﬁciency by means of an
amplicon dilution series. Amplicons were generated by performing a qPCR reaction with each of the 92
assays on human genomic DNA (Roche). Amplicons were pooled and a 10-fold dilution series ranging
from 2.107 to 2.101 molecules was generated using 5 ng l1 carrier RNA. Efﬁciencies were calculated by
combining amplicon concentrations and corresponding assay Cq-values in the following formula:
E= (10 − 1/S 1) × 100 with s= slope of the linear regression of log10 (concentrations) and Cq-values.
RNA isolation and reverse transcription
Cell pellets for each of the NCI60 cancer cell lines were obtained from the National Cancer Institute
(Developmental Therapeutics Program). RNA was isolated using the miRNeasy mini kit (Qiagen)
according to the manufacturer’s instructions. RNA concentration was measured using the Nanodrop
spectrophotometer. RNA from the NCI60 cancer cell line panel and MAQC samples was reverse
transcribed using the iScript SsoAdvanced kit (Bio-Rad) with 4 μg of input RNA according to the
manufacturer’s instructions.
qPCR
A total of 1707 lncRNA assays were spotted in triplicate on a SmartChip (Wafergen) to obtain a ﬁnal
concentration of 250 mM primer in a 100 nl reaction volume (Wafergen SmartChip Human lncRNA-1
Panel V1.0, cat n° 430-000103). Per sample, one SmartChip was prepared. A reaction mix containing 4 μg
of cDNA (20 μl), 340 μl of 2 X SsoAdvanced Universal SYBR Green Supermix (Bio-Rad), 6.8 μl of BSA
(Wafergen), 1.36 μl of yeast cocktail (Wafergen) and 311.8 μl H2O was dispensed in each well of the
SmartChip to obtain a volume of 100 nl per well. SmartChips were analyzed on a SmartChip Real-Time
PCR System using the SmartChip qPCR software (version 2.5.3.69).
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Figure 2. Technical validation of the lncRNA proﬁling platform. (a) Mean Cq-values of 92 lncRNA assays in
function of the molecule concentration used in the standard dilution series. Error bars represent the standard
deviation of replicate measurements. (b) Distribution of efﬁciencies for all 92 assays. (c) Cq-correlation plot for
replicate MAQC samples. Assays with Cq-value>28 in one or both replicates were set to 28 and color coded
red. (d) MAQC titration response curve showing the percentage of titrating assays in relation to the expression
difference between MAQCA and MAQCB.
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Data processing and normalization
Raw Cq-values (Data Citation 1) were ﬁltered based on a detection threshold of 28 PCR cycles, excluding
measurements with Cq> 28. This cutoff was derived from the miRNA Quality Control study and
represents the Cq-value above which reproducible detection is no longer possible10. The median Cq-value
of triplicate measurements per gene was subsequently used to calculate a sample-speciﬁc normalization
factor, applying the global mean normalization strategy11. Brieﬂy, each Cq-value was normalized by
subtracting the mean Cq-value per sample. Normalized Cq-values were multiplied by -1 such that higher
values represent higher expression levels (Data Citation 1 and Supplementary Table 2).
Data Records
Raw and normalized Cq-values resulting from the RT-qPCR measurements of 1707 lncRNAs in the
NCI60 cancer cell lines can be found in the Gene Expression Omnibus (Data Citation 1).
Technical Validation
Experimental assay validation
Assay efﬁciency was determined for a random selection of 92 lncRNA assays using a standard dilution
series. Optimal efﬁciency, generally considered between 90% and 110%, was observed for all tested assays
(Fig. 2a,b).
Assay reproducibility and titration response
Platform reproducibility was validated by replicate measurements of MAQCA RNA (r= 0.976,
Figure 2c). Assay titration response was evaluated by proﬁling all four MAQC samples. The percentage
of titrating assays was calculated in function of the expression difference between MAQCA and MAQCB
and, as expected, increased with an increasing difference between MAQCA and MAQCB (Fig. 2d). The
observed titration response was in line with previously reported titration response results for high-
throughput RT-qPCR platforms10.
NCI60 lncRNA expression data
The NCI60 cancer cell line panel consists of 60 cell lines representing 9 different cancer types. As
lncRNAs are known to be differentially expressed between tissue and cancer types12,13, lncRNA
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Figure 3. Validation of the NCI60 lncRNA expression data. (a) Hierarchical clustering of NCI60 cell lines
according to the lncRNA expression data. Cancer types are color-coded. LncRNA expression values are shown
as a heatmap. (b) Hierarchical clustering of NCI60 cell lines according to public mRNA expression data.
(c) Expression of ANRIL and PVT1 in cell lines with differential ANRIL and PVT1 copy number.
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expression proﬁles should be able to classify the cell lines in the NCI60 panel. The lncRNA expression
proﬁles in this dataset were ﬁltered to retain only those lncRNAs expressed in at least 80% of the samples
per cancer type. Hierarchical clustering of the NCI60 cell lines based on the expression of 1109 lncRNAs
showed similar classiﬁcation accuracy as compared to clustering using expression data from 19,185
mRNAs, obtained from publicly (http://discover.nci.nih.gov/cellminer/) available mRNA expression data
(Fig. 3a,b). To further support the technical quality of the NCI60 lncRNA expression dataset, we
evaluated the expression of two well-established dosage-sensitive lncRNAs, ANRIL (copy number
deletion14) and PVT1 (copy number ampliﬁcation15), in relation to their matching copy number status in
the NCI60 cell lines. As expected, ANRIL expression was signiﬁcantly down regulated in cell lines with
ANRIL copy number loss whereas PVT1 was signiﬁcantly up regulated in cell lines with PVT1 copy
number ampliﬁcation (Mann-Whitney Po0.05, Fig. 3c). These results demonstrate that the lncRNA
expression proﬁles that have been generated match the phenotypic and genomic characteristics of the
cancer cell lines, underscoring the technical quality of the NCI60 RT-qPCR lncRNA expression dataset.
Technical quality could also be validated by direct comparison of the RT-qPCR data with matching
microarray data obtained from the Cancer Cell Line Encyclopedia. When comparing expression values
for 3 well studied lncRNAs (MALAT1, NEAT1 and TUG1), a signiﬁcant positive correlation between
both datasets was observed (Spearman Rank, Po0.01). The quality and applicability of this dataset is
further exempliﬁed by a recent study in which the expression of the melanoma-speciﬁc lncRNA
SAMMSON was validated using the NCI60 lncRNA expression proﬁles presented here6.
Usage Notes
Researchers interested in integrating the lncRNA expression data with matching omics datasets (copy
number, mRNA expression, miRNA expression, protein expression, mutation, methylation), drug activity
scores or cell line metadata can use the CellMiner webtool (http://discover.nci.nih.gov/cellminer/) to
download the respective datasets. Associations between lncRNAs and the above mentioned data layers
can be studies through correlation analysis or alternative methods across the 60 cell lines. These include
for example correlation analysis between lncRNA and mRNA expression data across cell lines or
correlation analysis between lncRNA expression and IC50 values for various compounds across cell lines.
Note that lncRNAs are expressed in a more tissue-restricted manner as compared to protein-coding
genes, explaining why some lncRNAs only have expression values in a subset of the samples.
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